CALB2 and ovarian cancer: Consistent with our results, higher serum calretinin concentration at diagnosis, as well as its dynamics during chemotherapy, were independent predictors of poor PFS and OS, as well as chemotherapy resistance, in ovarian cancer patients treated with cisplatin-based chemotherapy [24].